Skip to main content
SpringerLink
Log in

Peptide Imaging

  • Chapter
Diagnostic Nuclear Medicine

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 1458 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adamou A, Aiyar N, van Horn S, Elshourhagy NA (1996) Cloning and functional characterization of human vasoactive intestinal peptide (VIP)-2 receptor. Biochem Biophys Res Commun 209:383–392

    Google Scholar 

  • Ain KB, Taylor KD (1994) Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1097–1102

    Article  CAS  PubMed  Google Scholar 

  • Ain KB, Taylor KD, Tofiq S, Venkataraman G (1997) Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines. J Clin Endocrinol Metab 82:1857–1862

    Article  CAS  PubMed  Google Scholar 

  • Achilefu S, Srinivasan A, Schmidt MA, Jimenez HN, Bugaj JE, Erion JL (2003) Novel bioactive and stable neurotensin peptide analogue capable of delivering radiopharmaceuticals and molecular beacons to tumor. J Med Chem 46:3403–3411

    Article  CAS  PubMed  Google Scholar 

  • Alexander RW, Upp Jr JR, Poston GJ, Gupta V, Townsend Jr CM, Thompson JC (1988) Effects of bombesin on human small cell carcinoma in vivo. Cancer Res 48:1439–1441

    CAS  PubMed  Google Scholar 

  • American Cancer Society (1991) Cancer facts and figures 1991. American Cancer Society, Atlanta

    Google Scholar 

  • Anderson CJ, Dehdeshti F, Cutler PD et al (2001) 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 42:213–221

    CAS  PubMed  Google Scholar 

  • Bakker Wh, Alberts R, Bruns C, Breeman WAP, Hofland LJ, Marbach P, Pless J, Pralet D, Stolz B, Koper JW, Lamberts SWJ, Visser TJ, Krenning EP (1991) [111In-DTPA-D-PHE1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumours: synthesis, radiolabelling and in vitro validation. Life Sci 49:1583–1591

    CAS  PubMed  Google Scholar 

  • Balthazar EJ, Chako AC (1990) Computed tomography of pancreatic masses. Am J Gastroenterol 85:343–349

    CAS  PubMed  Google Scholar 

  • Bangard M, Behe M, Bender H, Guhlke S, Risse J, Grünwald F, Mäcke H, Biersack HJ (1998) Technetium-99m-octreotide for the detection of somatostatin receptor positive (SSTR+) tumors: preliminary results. Eur J Nucl Med 25:837

    Google Scholar 

  • Battari A, Martin JM, Luis J, Pouzol O, Secchi J, Marvaldi J, Pichon J (1988) Solubilization of the vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J Biol Chem 263:17685–17689

    PubMed  Google Scholar 

  • Baudin E, Schlumberger M, Lumbroso J, Travagli JP, Caillou B, Parmentier C (1996) Octreotide scintigraphy in patients with differentiated thyroid carcinoma: contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 81:2541–2545

    Article  CAS  PubMed  Google Scholar 

  • Behr TM, Behe MP (2002) Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med 32:97–109

    PubMed  Google Scholar 

  • Behr TM, Behe M, Angerstein C et al (1999) Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential. Clin Cancer Res 5:3124s–3138s

    CAS  PubMed  Google Scholar 

  • Behe M, Behr TM (2003) Cholecystokinin-B (CCK.B) / gastrin receptor targeting for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers 66:399–418

    Google Scholar 

  • Bell GI, Yasada K, Kong H (1995) Molecular biology of somatostatin receptors. Ciba Found Symp 190:65–88

    CAS  PubMed  Google Scholar 

  • Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J (2003) Somatostatin receptor 2 and 5 are the major somatostatin receptors in insulinomas; an in vivo and in vitro study. J Clin Endocrinol 88:5353–5360

    CAS  Google Scholar 

  • Black RJ, Bray F, Ferlay J, Parkin DM (1997) Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33:1075–1107

    Article  CAS  PubMed  Google Scholar 

  • Blaker M, de Weerth A, Tomettem M, Schulz M, Hoppner W, Arlt D, Hoang-Vu C, Dralle H, Terpe H, Jonas L, von Schrenck T (2002) Expression of cholecytochinin-2 receptor in normal human thyroid gland and medullary thyroid carcinoma. Eur J Endocrinol 146:89–96

    Article  CAS  PubMed  Google Scholar 

  • Bloom SR, Polak JM, Pearse AGE (1973) Vasoactive intestinal peptide and watery diarrhea syndrome. Lancet ii:14–16

    Google Scholar 

  • Blum J, Handmaker H, Rinne N (1999) The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 115:224–232

    Article  CAS  PubMed  Google Scholar 

  • Bogatzky J, Guhlke S, Bender H, Sartor J, Knapp FF, Biersack HJ (1997) Receptor binding studies with rhenium-RC160, a directly-labeled somatostatin analog, with membranes of the colon cancer cell line HT 29, CHO cells and ovary carcinoma cell line EFO-21. Eur J Nucl Med 24:1059A

    Google Scholar 

  • Bombardieri E, Crippa F, Maffioli L, Greco M (1997) Nuclear medicine techniques for the study of breast cancer. Eur J Nucl Med 24:809–824

    CAS  PubMed  Google Scholar 

  • Boring CC, Squires TS, Tong T, Montgomery S (1994) Cancer statistics 1994. CA Cancer J Clin 44:7–26

    CAS  PubMed  Google Scholar 

  • Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Livier J, Guellemin R (1973) Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 119:77–79

    Google Scholar 

  • Breeman WA, Hofland LJ, de Jong M, Bernard BF, Srinivasan A, Kweekeboom DJ, Visser TJ, Krenning EP (1999) Evaluation of radiolabelled bombesin analogues for receptor-targeted scintigraphy and radiotherapy. Int J Cancer 81:658–665

    Article  CAS  PubMed  Google Scholar 

  • Breeman WA, de Jong M, Erion JL, Bugaj JE, Srinivasan A, Bernard BF, Kweekeboom DJ, Visser TJ, Krenning EP (2002) Preclinical comparison of (111)In-labeled DTPA-or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med 43:1650–1656

    CAS  PubMed  Google Scholar 

  • Buchegger F, Bonvin F, Kosinski M, Schaffland AO, Prior J, Reubi JC, Blauenstein P, Tourwe D, Garcia Garayoa E, Bischof Delaloye A (2003) Radiolabeled neurotensin analog, 99Tc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients. J Nucl Med 44:1649–1654

    CAS  PubMed  Google Scholar 

  • Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Luis F, Vaysse N, Susini C (1996) Loss of SSTR2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 54:1823–1827

    Google Scholar 

  • Caroll RE, Caroll R, Benya RV (1999) Charcterization of gastrin-releasing peptide receptors aberrantly expressed by non-abtral gastric adenocarcinomas. Peptides 20:229–237

    Google Scholar 

  • Camby I, Salmon I, Oiry C, Galleyrand JC, Nagy N, Danguy A, Brotchi J, Pateels JL, Martinez J, Kiss R (1996) The influence of gastrin and/or cholecytokinin antagonists on the proliferation of three human astrocytic tumor cell lines. Neuropeptides 30:433–437

    CAS  PubMed  Google Scholar 

  • Capello A, Breeman WAP, van Hagen PM, Krenning EP, de Jong M (2003) Increased apoptosis induction with a RDG linked somatostatin analogue. Eur J Nucl Med Mol Imaging 30[Suppl 2]:396

    Google Scholar 

  • Chabry J, Labbe-Jullie C, Glly D, Kitabgi P, Vincent JP, Mazella J (1994) Stable expression od the cloned rat brain neurotensin receptor into fibroblasts: binding properties, photoaffinity labeling, transduction mechanisms, and internalization. J Neurochem 63:19–27

    CAS  PubMed  Google Scholar 

  • Chen J, Cheng Z, Hoffman TJ et al (2000) Melanoma-targeting properties of 99mtechnetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues. Cancer Res 60:5649–5658

    CAS  PubMed  Google Scholar 

  • Christian JA, Cook GJ, Harmer C (2003) Indium-111-labelled octreotide scintigraphy in the diagnosis and management of non-iodine avid metastatic carcinoma of the thyroid. Br L Cancer 89:258–261

    CAS  Google Scholar 

  • Clarke SEM (1998) Medullary thyroid carcinoma. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and treatment, vol 2. Churchill-Livingstone, Edinburgh, pp 959–968

    Google Scholar 

  • Corness JD, Demchyschyn LL, Seeman P (1993) A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS 321:279–284

    Article  CAS  Google Scholar 

  • Couvineau A, Laburthe M (1985) The human vasoactive intestinal peptide receptor: molecular identification by covalent cross-linking in colonic epithelium. J Clin Endocrinol Metab 61:50–55

    CAS  PubMed  Google Scholar 

  • Couvineau A, Amiranoff B, Laburthe M (1986) Solubilization of the liver vasoactive intestinal peptide receptors. J Biol Chem 261:14482–14489

    CAS  PubMed  Google Scholar 

  • Couvineau A, Voisin T, Guijarro L, Laburthe M (1990) Purification of vasoactive intestinal peptide receptor from porcine liver by a newly designed one-step affinity chromatography. J Biol Chem 265:13386–13390

    CAS  PubMed  Google Scholar 

  • Couvineau A, Rouyer-Fessard C, Darmoul D, Maoret JJ, Carrero I, Ogier-Denis E Laburthe M (1994) Human intestinal VIP receptor: cloning and functional expression of two cDNA encoding proteins with different N-terminal domains. Biochem Biophys Res Commun 200:769–776

    Article  CAS  PubMed  Google Scholar 

  • DeCosse JJ, Tsoulias GJ, Jacobson JS (1994) Colorectal cancer: detection, treatment and rehabilitation. CA Cancer J Clin 44:27–42

    CAS  PubMed  Google Scholar 

  • De Jong M, Bernard BF, de Bruin E et al (1998a) Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nucl Med Commun 19:283–288

    PubMed  Google Scholar 

  • De Jong M, Breeman WA, Bakker WH et al (1998b) Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res 58:437–441

    PubMed  Google Scholar 

  • Decristoforo C, Mather SJ, Cholewinski W et al (2000) 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivates. Eur J Nucl Med 27:1318–1325

    CAS  PubMed  Google Scholar 

  • Decristoforo C, Maina T, Nock B, Gabriel M, Cordopatis P, Moncayo R (2003) 99mTc-Demotate 1: first data in tumour patients-results of a pilot/phase I study. Eur J Nucl Med Mol Imaging 30:1211–1219

    Article  CAS  PubMed  Google Scholar 

  • Demchyschyn LL, Srikant CB, Sunahara RK, Kent G, Seeman P, van Tol HH, Panetta R, Patel YC, Niznik HB (1993) Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20. Mol Pharmacol 43:894–901

    Google Scholar 

  • Dockray GJ (2000) Gastrin, growth, and colonic neoplasia. Gut 47:747–748

    Article  CAS  PubMed  Google Scholar 

  • Donovan DT, Gagel RF (1997) Medullary thyroid carcinoma and the Multiple Endocrine Neoplasia Syndromes. In: Falk A (ed) Thyroid diseases: endocrinology, surgery, nuclear medicine and radiotherapy. Lippincott-Raven, Philadelphia, pp 619–644

    Google Scholar 

  • Duet M, Sauvaget E, Petelle B, Rizzo N, Guichard JP, Wassef M, Le Cloirec J, Herman P, Tran Ba Huy P (2003) Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med 44:1767–1774

    PubMed  Google Scholar 

  • Ehlers RA, Kim Sh, Zhang Y, Ethridge RT, Murrilo C, Hellmich C, Evans DB, Townsend CM Jr, Mark Evers B (2000) Gut peptide receptor expression inhuman pancreatic cancer. Ann Surg 231:838–848

    Article  CAS  PubMed  Google Scholar 

  • Egli A, Alberto R, Tannahill L et al. Organometallic 99mTc-aquaion labels peptide to an unprecedented high specific activity. J Nucl Med 1999; 40: 1913–1917.

    CAS  PubMed  Google Scholar 

  • Fathi Z, Corjay MH, Shapira H, Wada E, Benya R, Jensen R, Viallet J, Sausville EA, Battey JF (1993) BRS-3: novel bombesin receptor subtype selectivity expressed in testis and lund carcinoma cells. J Biol Chem 268:5979–5984

    CAS  PubMed  Google Scholar 

  • Ferrari S, Dondi M, Fanti S, Giacomini S, Mercuri M, Bacci G 2003 Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm 18:8847–8851

    Article  Google Scholar 

  • Ferris HA, Carroll RE, Creswick KC, Banya RV (1997) Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells. Peptides 18:663–672

    Article  CAS  PubMed  Google Scholar 

  • Fisher WE, Doran TA, Muscarella II P, Boros LG, Ellison EC, Schirmer WJ (1998) Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J Natl Cancer Inst 90:322–324

    Article  CAS  PubMed  Google Scholar 

  • Fleischmann A, Laderach U, Friess H, Buechler MW, Reubi JC (2000) Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab Invest 80:1807–1817

    CAS  PubMed  Google Scholar 

  • Florio T, Montella L, Corsaro A, De Chiara A, Apice G, Fazioli F, Lastoria S, Schettini G, Palmieri G (2003) In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. Anticancer Res 23:2465–2471

    CAS  PubMed  Google Scholar 

  • Foekens JA, Portengen H, Putten WLJ (1989) Prognostic value of receptors for insulin-like growth factor 1, somatostatin and epidermal growth factor in human breast cancer. Cancer Res 49:7002–7009

    CAS  PubMed  Google Scholar 

  • Freeny PC, Marks WM, Ryan JA, Traverso LW (1988) Pancreatic ductal adenocarcinoma: 2 diagnosis and staging with dynamic CT. Radiology 166:125–133

    CAS  PubMed  Google Scholar 

  • Friess H, Zhu Z, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Büchler MW (2003) Neurokinin-1 receptor (NK-1R) expression and potential effects on tumor growth in human pancreatic cancer. Lab Invest 83:731–742

    CAS  PubMed  Google Scholar 

  • Fujita T, Yamaji Y, Sato M, Murao K, Takhara J (1994) Gene expression of somatostain receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines. Life Sci 55:1797–1806

    CAS  PubMed  Google Scholar 

  • Gabriel M, Decristoforo C, Donnemiller E, Ulmer H, Watfah Rychhhlinski C, Mather SJ, Moncayo R (2003) An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors. J Nucl Med 44:708–716

    CAS  PubMed  Google Scholar 

  • Garcia-Garayoa E, Allemann-Tannahill L, Blauenstein P et al (2001) In vitro and in vivo evaluation of new radiolabeled neurotensin(8–13) analogues with high affinity for NT1 receptors. Nucl Med Biol 28:75–84

    CAS  PubMed  Google Scholar 

  • Garcia-Garayoa E, Blauenstein P, Bruehlmeier M et al (2002) Preclinical evaluation of a new, stabilized neurotensin(8–13) pseudopeptide radiolabeled with 99mTc. J Nucl Med 43:374–383

    CAS  PubMed  Google Scholar 

  • Garin E, Devillers A, Le Cloirec J, Bernard AM, Lescouarché J, Herry JY, Reubi JC, Bourguet P (1998) Use of In-111-penetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake. Eur J Nucl Med 25:687–694

    Article  CAS  PubMed  Google Scholar 

  • Gespach C, Bawab W, de Cremoux P, Calvo F (1988) Pharmacology, molecular identification and functional characteristics of vasoactive intestinal peptide receptors in human breast cancer. Cancer Res 48:5079–5083

    CAS  PubMed  Google Scholar 

  • Giblin MF, Wang N, Hoffmann TJ, Jurisson SS, Quinn TP (1998) Design and characterization of á melanotropin peptide analogs cyclized through rhenium and technetium metal coordination. Proc Natl Aad Sci USA 95:12814–12818

    CAS  Google Scholar 

  • Ginsberg RJ, Kris MG, Armstrong JG (1993) Cancer of the lung. In: De Vita V, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology, 4th edn. Lippincott, Philadelphia, pp 673–723

    Google Scholar 

  • Giusti M, Ciccarelli, Dallabonzana D, Delitala G, Faglia G, Liuzzi A, Gussoni G, Disem GG (1997) Clinical results of long term slow release lanreotide treatment of acromegaly. Eur J Clin Invest 27:277–284

    Article  CAS  PubMed  Google Scholar 

  • Guitera-Rovel P, Lumbroso J, Gautier-Gouis MS, Spatz A, Mercier S, Margulis A, Mamelle G, Kolb F, Lartigau E, Avril MF (2001) Indium-111-octreotide scintigraphy of Merkel call carcinomas and their metastases. Ann Oncol 12:807–811

    Article  CAS  PubMed  Google Scholar 

  • Godwin JD (1975) Carcinoid tumors: an analysis of 2837 cases. Cancer 36:560–569

    PubMed  Google Scholar 

  • Gotthart M, Battmann A, Beuter D, Bauhofer A, Schipper ML, Béhé P, Klose KJ, Behr TM (2003) In-111-DTPA-D-Glu1-Minigastrin is superior to F-18-FDG PET and CT in the diagnosis of metastatic medullary thyroid cancer. Eur J Nucl Med Mol Imaging 30:S158

    Google Scholar 

  • Greenman Y, Melmed S (1994a) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398–403

    Article  CAS  PubMed  Google Scholar 

  • Greenman Y, Melmed S (1994b) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729

    Article  CAS  PubMed  Google Scholar 

  • Gugger M, Reubi JC (1999) Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am J Pathol 155: 2067–2076

    CAS  PubMed  Google Scholar 

  • Guhlke S, Zamora PO, Sartor J, Knapp FF, Rhodes BA, Biersack HJ (1997) Stabilization of rhenium-188 and iodine-131 labeled peptides for radiotherapy. Eur J Nucl Med 24:1059A

    Google Scholar 

  • Haegerstrand A, Jonzon B, Daalsgard CJ, Dalsgaard CJ, Nilsson J (1989) Vasoactive intestinal polypeptide stimulates cell proliferation and adenylate cyclase activity of cultured human keratinocytes. Proc Natl Acad Sci USA 86:5993–5996

    CAS  PubMed  Google Scholar 

  • Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA (1998) International union of pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and piutiary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265–270

    CAS  PubMed  Google Scholar 

  • Haubner R, Wester HJ, Reuning U, Senekowitsch-Schmidtke R, Diefenbach B, Kessler H, Stöckin G and Schwaiger M (1999) Radiolabeled avb3 integrin antagonists: a new class of tracer for tumor targeting. J Nucl Med 40:1061–1971

    CAS  PubMed  Google Scholar 

  • Haubner R, Wester HJ, Mang C, Senekowitsch-Schmidtke R, Kessler H and Schwaiger M (2000) Synthesis and first evaluation of a [18F]SAA-labeled RDG-peptide for monitoring the avb3 integrin expression. J Nucl Med 41:42P

    Google Scholar 

  • Hejna M, Kurtaran A, Raderer M, Pangerl T, Niederle B, Vorbeck F, Vierhapper H, Angelberger P, Virgolini I (1998) 123I-vasoactive intestinal peptide (VIP) receptor and 111In-DTPA-Phe1-octreotide scanning in patients with insulinoma. Eur J Nucl Med 25:977A

    Google Scholar 

  • Henning IM, Laissue JA, Horisberger U, Reubi JC (1995) Sbstance P receptors in human primary neoplasms: tumoural and vascular localisation. Int J Cancer 61:786–792

    Google Scholar 

  • Henze J, Schuhmacher P, Hipp A, Dimitrakopoulou-Strauss H, Maecke R, Strauss LG, Haberkorn U (2003a) 68GA-DOTA°-D Phe1-Tyr3-Octreotide (DOTATOC) kinetics in the follow-up of irradiated meningeomas. Annual meeting of the Society of Nuclear Medicine, abstract 381

    Google Scholar 

  • Henze J, Schuhmacher P, Hipp A, Dimitrakopoulou-Strauss H, Maecke R, Strauss LG, Haberkorn U (2003b) Kinetic analyis of 68GA-DOTA°-D Phe1-Tyr3-Octreotide (DOTA-TOC) in untreated meningeomas. Annual meeting Society of Nuclear Medicine, New Orleans 2003, abstract 880

    Google Scholar 

  • Hofmann M, Maecke H, Borner R, Weckesser E, Schoffski P, Oei L, Schumacher J, Henze M, Heppeler A, Meyer J, Knapp H (2001) Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med 28(12):1751–1757

    CAS  PubMed  Google Scholar 

  • Hofmann M, Boerner A, Meyer G, Maecke H, Berding G, Oei M, Clauss R, Knapp WH (2003) Use of SUV in Ga-68-DOTA-TOC PET-Influence of varying peptide amout. Eur J Nucl Med Mol Imaging 30:S204

    Google Scholar 

  • Hoffmann TJ, Gali H, Smith CJ, Sieckman GL, Hayes DL, Owen NK, Volkert WA (2003) Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide reeptors expressed on human pancreate cancer cells. J Nucl Med 44:823–831

    Google Scholar 

  • Hillairet de Boiferon M, Raguin O, Thiercelin C, Dussaillant M, Rostene W, Barbet J, Pelegrin A, Gruaz-Guyon A (2002) Improved tumor selectivity of radiolabeled peptides by receptor and antigen dual targeting in the neurotensin receptor model. Bioconjug 13:654–662

    Google Scholar 

  • Hoegerle S, Altenhofer C, Ghanem N, Koehler N, Waller CF, Sheruebl, Moser E, Nitzsche E (2001) Whole-body 18F-Dopa PET for detection of gastrointestinal carcinoid tumor. Radiology 220:373–380

    CAS  PubMed  Google Scholar 

  • Hoegerl S, Altenhoefer C, Ghanem N, Brink I, Moser E, Nitze E (2003b) 18F-DOPA positron emission tomography for tumor detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med Mol Imaging 28:64–71

    Google Scholar 

  • Hökfelt T, Pernow B, Wahren J (2001) Substance P: a pioneer among neuropeptides. J Intern Med 249:27–40

    PubMed  Google Scholar 

  • Hustinx R, Paulus P, Foidart J, Bury T, Cataldo D, Rigo P (1997) Efficacy of Tc 99 m P829, a radiolabeled somatostatin analog, in visualising mediastinal spread of non-small cell lung cancer. Eur J Nucl Med 24:959A

    Google Scholar 

  • Inagaki N, Yoshida H, Mizuta M, Mizuno N, Fujii Y, Gonoi T, Miyazaki JI, Seino S (1994) Cloning and functional characterization of a third pituitary adenylate cyclase-activating polypeptide subtype receptor-expressed in insulin-secreting cells. Proc Natl Acad Sci USA 91:2679–2683

    CAS  PubMed  Google Scholar 

  • Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, Ohshio G, Imamura M, Konishi J (1995) Value of fluorine-18-fluorodeoxyglucose and thallium 201 in the detection of pancreatic cancer. J Nucl Med 36:229–235

    CAS  PubMed  Google Scholar 

  • Ishihara T, Shigemoto R, Mori K, Takahashi K, Nagata S (1992) Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide. Neuron 8:811–819

    Article  CAS  PubMed  Google Scholar 

  • Jagoda E, Aloi L, Seidel J, Lang L, Moody T, Green S, Caraco C, Daube Witherspoon M, Green MV, Eckelman WC (1997) The biodistribution of a F-18 labeled derivate of vasoactive intestinal peptide (dVIP) in a xenograft mouse model of breast cancer. J Nucl Med 38:239A

    Google Scholar 

  • Jais P, Terris B, Ruszniewski, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M, Lewin MGM (1997) Somatostatin receptor subtype gene expression in human endocrine gastroenteropancreatic tumors. Eur J Clin Invest 27:639–644

    Article  CAS  PubMed  Google Scholar 

  • Janson ET, Gobl A, Kälkner KM, Ölber K (1996) A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization of somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56:2561–2565

    CAS  PubMed  Google Scholar 

  • Jiang S, Kopras E, McMichael M, Bell RH Jr, Ulrich CD (1997) Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor bearing human pancreatic adenocarcinoma derived cells. Cancer Res 57:1475–1480

    CAS  PubMed  Google Scholar 

  • John M, Meyerhof W, Richter D, Waser B, Schaer JC, Scherübl H, Boese-Landgraf J, Neuhaus P, Ziske C, Mölling K, Riecken EO, Reubi JC, Wiedenmann B (1996) Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut 38:33–39

    CAS  PubMed  Google Scholar 

  • Kahn A, Herman P, Vorwecki P (1991) Solitary pulmonary nodules: comparison and classification with standard, thin section, and reference phantom CT. Radiology 179:477–481

    Google Scholar 

  • Kalser MH, Barkin J, MacIntyre JM (1985) Pancreatic cancer: assessment of prognosis by clinical presentation. Cancer 56:397–402

    CAS  PubMed  Google Scholar 

  • Kelly DM, Benjamin IS (1995) Pancreatic carcinoma. Ann Oncol 6:19–28

    CAS  PubMed  Google Scholar 

  • Kienast O, Dobrozemsky G, Özer S, Traub T, Novotny C, Niederle B, Raderer M, Kainberger F, Dudczak R, Kurtaran A (2003) Clinical impact of image fusion by means of XCT/SPECT: Vienna experience with 111In-labeled somatostatin analogues, 123I-MIBG and 131I-WBS. Eur J Nucl Med 30:S182

    Google Scholar 

  • Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U (2003) Evaluation of positron emission tomography imaging using [68Ga]-Dota-DPhe(1)-Tyr(3)-ocreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol 5:42–48

    PubMed  Google Scholar 

  • Krausz Y, Keidar Z, Kogan I, Even-Sapir E, Bar-Schalom R, Engel A, Rubinstein R, Sachs J, Bocher M, Agranovicz S, Chisin R, Israel O (2003) SPECT/CT hybrid imaging with 111In-pentreotide in assessment of neuroendocrine tumours. Clin Endocrinol 59:565–573

    Article  Google Scholar 

  • Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausem L, Lamberts JS, Reubi JC, Lamberts SW et al (1989) Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1:242–244

    CAS  PubMed  Google Scholar 

  • Krenning EP, Bakker WH, Kooij PPM, Breeman WAP, OEI HY, de Jong M, Reubi JC, Visser TJ, Bruns C, Kwekkeboom DJ, Reijs AEM, van Hagen PM, Koper JW, Lamberts SWJ (1992) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide in man: metabolism, dosimetry and comparison with [123I-Tyr-3-]-octreotide. J Nucl Med 33:652–658

    CAS  PubMed  Google Scholar 

  • Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei Hy, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with (111In-DOTA-d-Phe1)-and (123I-Thyt3)-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 18:1–16

    Google Scholar 

  • Krenning EP, Kooij PP, Bakker WH, Breeman WH, Postema PT, Kwekkeboom DJ, Oei HY, Jong M, Visser TJ, Reijs AE (1994) Radiotherapy with a radiolabeled somatostatin analogue, 111In-DTPA-D-Phe1-octreotide. A case history. Ann NY Acad Sci 733:496–504

    CAS  PubMed  Google Scholar 

  • Krenning EP, Kooij PP, Pauwels S, Breeman WA, Postema PT, Herder de WW, Valkema R, Kwekkeboom DJ (1996) Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 57:57–61

    CAS  PubMed  Google Scholar 

  • Krenning EP, Bakker WH, Kwekkeboom DJ, Kooij PPM, van der Pluijm ME, Behe M, Mäcke H (1997) Biodistribution of a new chelated somatostatin analogue, [In-111-DOTAD-Phe1-Tyr3]-octreotide; comparison with [In-111-DTPAD-Phe-1]-octreotide in humans. J Nucl Med 38:103A

    Google Scholar 

  • Krois D, Riedel C, Angelberger P, Kalchberger P, Virgolini I, Lehner H (1996) Synthesis of N-a-(6-hydrazinonicotinoyl)-octreotide: a precursor of a 99mTc-complex. Liebigs Ann 1463–1469

    Google Scholar 

  • Kubota A, Yamada Y, Kagimoto S, Kagimoto S, Shimatsu A, Imamura M, Suda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201–995 in treatment of human endocrine tumors. J Clin Invest 93:1321–1325

    CAS  PubMed  Google Scholar 

  • Kurtaran A, Pangerl T, Scheuba C, Schima W, Schober E, Kaserer K, Teleky B, Virgolini I (1997) Vasualization of intestinal splenosis by somatostatin receptor scintigraphy. Am J Gastroenterol 93:1375–1376

    Google Scholar 

  • Kurtaran A, Scheuba C, Kaserer K, Angelberger P, Niederle B, Virgolini I (1998) Comparison of 111In-DTPA-D-Phe1-octreotide and 99mTc-(V)-dimercapto-succinic acid scanning in the preoperative localisation of medullary thyroid carcinoma. J Nucl Med 39:1907–1909

    CAS  PubMed  Google Scholar 

  • Kvols L (1994) Medical oncology considerations in patients with metastatic neuroendocrine tumors. Semin Oncol 21:56–60

    CAS  PubMed  Google Scholar 

  • Kwekkeboom D, Krenning E, Bakker W (1991) Radioiodinated somatostatin analog scintigraphy in small-cell lung cancer. J Nucl Med 32:1845–1848

    CAS  PubMed  Google Scholar 

  • Kwekkeboom DJ, Hoff AM, Lamberts SWJ et al (1992) Somatostatin analogue scintigraphy: a simple and sensitive method for the in visualisation of Merkel-cell tumors and their metastases. Arch Dermatol 128: 818–821

    Article  CAS  PubMed  Google Scholar 

  • Kwekkeboom DJ, van Urk H, Pauw KH et al (1993) Octreotide scintigraphy for detection of paragangliomas. J Nucl Med 34:873–878

    CAS  PubMed  Google Scholar 

  • La Bella R, Garcia-Garayoa E, Bahler M, Blauenstein P, Schibili R, Conrath P, Tourwe D, Schubiger PA (2002) A 99mTc (I)-postlabeled high affinity bombesin analogue as a potential tumor imaging agent. Bioconjug 13:599–604

    Google Scholar 

  • Laburthe M, Couvineau A (1988) Molecular analysis of vasoactive intestinal peptid receptors. A comparison with receptors for VIP-related peptides. In: Said S, Mutt V (eds) Vasoactive intestinal peptide and related peptides. NY Acad Sci 527:296–313

    Google Scholar 

  • Lamberts SWJ, Bakker WH, Reubi JC, Krenning EP (1990) Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246–1249

    CAS  PubMed  Google Scholar 

  • Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ (1996) Drug therapy: octreotide. N Engl J Med 334:246–254

    Article  CAS  PubMed  Google Scholar 

  • Lastoria S, Muto P, Caracò C, Vergara P, Varrella L, Pezullo F, Ionna F, Mozillo N, Lister-James J, Salvatore M (1996) Somatostatin receptor scintigraphy (SRS) with technetium −99 m labeled synthetic peptides in melanoma. J Nucl Med 37:138A

    Google Scholar 

  • Laws SAM, Gough AC, Evans AA, Bains MA, Primrose JN (1997) Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer 75:360–366

    CAS  PubMed  Google Scholar 

  • Lebtahi R, LeCloirec J, Houzard JC et al (2002) Detection of neuroendocrine tumors: 99mTc-P829-scintigraphy compared with 111 In-pentreotide scintigraphy. J Nucl Med 43:889–895

    CAS  PubMed  Google Scholar 

  • Leimer M, Kurtaran A, Raderer M, Smith-Jones P, Bischof C, Valencak J, Scima W, Lister-James J, Virgolini I (1998a) In vitro and in vivo binding of 99mTc-P829 to gastrointestinal adenocarcinomas. Eur J Nucl Med 39:923A

    Google Scholar 

  • Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, Vorbeck F, Niederele B, Virgolini I (1998b) Response to treatment with 90Y-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 39:2090–2094

    CAS  PubMed  Google Scholar 

  • Leimer M, Traub T, Andreae F, Angelberger P, Ofluoglu S, Stelzer O, Zettnig G, Kurtaran A, Flores J, Dudczak R, Virgolini I (2000) Binding of 111In-DOTA-lanreotide and 111In-DOTA-Tyr3-DPHE1-octreotide to thyroid. Eur J Nucl Med 27:A7010

    Google Scholar 

  • Li S, Kurtaran A, Li M, Traub-Weidinger T, Kienast O, Schima W, Angelberger P, Virgolini I, Raderer M, Dudczak R (2003) 111In-DOTA-dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study. Eur J Nucl Med Mol Imaging 30:1087–1095

    Article  CAS  PubMed  Google Scholar 

  • Lister-James J, Virgolini I, Nelson CA, Pearson DA, Leimer M, Moyer BR, Wilson DM, Dean RT (1998) Tc-99 m 1666: development of a technetium-99m-labeled VIP-receptor imaging agent. J Nucl Med 39:225A

    Google Scholar 

  • Lowe V, Fletcher J, Gobar L et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 16:1075–1084

    CAS  PubMed  Google Scholar 

  • Lugtenburg PJ, Löwenberg B, Eljkemans MJC, Habbema JDF, Lamberts R, Valkema R, Krenning EP (1998) Somatostatin receptor scintigraphy in limited Hodgkin’s disease: clinical impact and cost-effectiveness analysis. J Nucl Med 39:39A

    Google Scholar 

  • Lugtenburg PJ, Krenning EP, Valkema R, Oei HY, Lamberts SW, Eijkemans MJ, van Putten WL, Loewnberg B (2001) Somatostatin receptor scintigraphy useful in stage I–II Hodgkin’s disease: more extended disease identified. Br J Haematol 112:936–944

    Article  CAS  PubMed  Google Scholar 

  • Lutz EM, Sheward WJ, West KM, Fink G, Harmar AJ (1993) The VIP2 receptor: molecular characterization of a cDNA encoding a novel receptor for vasoactive intestinal peptide. FEBS Lett 334:3–8

    Article  CAS  PubMed  Google Scholar 

  • Mailleux P, Vanderhaeghen JJ (1990) Cholecytochinin receptors of A type in the human dorsal medulla oblongata and meningenomas, and og B type in small cell lung cancer. Nature 316:823–825

    Google Scholar 

  • Maina T, Stolz B, Albert R, Bruns C, Koch P, Maecke H (1994) Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219-387) labeled with technetium-99 m. Eur J Nucl Med 21:437–444

    Article  CAS  PubMed  Google Scholar 

  • Maina T, Nock B, Nikolopoulou A et al (2002) [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results. Eur J Nucl Med Mol Imaging 29:742–753

    Article  CAS  PubMed  Google Scholar 

  • Markwalder R, Reubi JC (1999) Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 59:1152–1159

    CAS  PubMed  Google Scholar 

  • Maoret JJ, Pospai D, Rouyer-Fessard C, Couvinnneau A, Laboisse C, Voisin T, Laburthe M (1994) Neurotensin receptor and its mRNA are expressed in many human colon cancer cell lines but not in normal colonic epithelium: binding studies and RT-PCR experiments. Biochem Biophys Res Commun 30:465–471

    Google Scholar 

  • Mather SJ, Ellison D (1994) Technetium-99 m labeled hybrid receptor binding peptides. J Nucl Med Biol 38:480–481

    Google Scholar 

  • Mazella J, Zsurger N, Navarro V, Chabry J, Kaghad M, Caput D, Ferrara P, Vita N, Gully D, Maffrand JP, Vincent JP (1998) The 100-kDa neurotensin receptor id gp95/sortilin, a non-G protein-coupled receptor. J Biol Chem 273:26273–26276

    Article  CAS  PubMed  Google Scholar 

  • Miller GM, Alexander JM, Bikkal HA, Katzenelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:2974–2979

    Google Scholar 

  • Moertel CG (1987) Karnovsky memorial lecture: an odyssee in the land of small tumors. J Clin Oncol 5:1503–1522

    Google Scholar 

  • Moody TW, Leyton J, Unsworth E, John C, Lang L, Eckelman WC (1998) (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors. Peptides 19:585–592

    CAS  PubMed  Google Scholar 

  • Moody TW, Chiles J, Casibang M, Moody E, Chan D, Davis TP (2001) SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides 22:109–115

    Article  CAS  PubMed  Google Scholar 

  • Muehllechner P, Gabriel M, Decristoforo C, Kendler D, Heute D, Donnemiller E, Moncayo R (2003) Somatostatin receptor scintigraphy using 99mTc-EDDA-HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 30:S285

    Google Scholar 

  • Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, Lehnert H (2003) Somatostatin receptor subtypes in human pheochromocytoma; subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 88:5150–5157

    Article  CAS  PubMed  Google Scholar 

  • Nagalla SR, Barry BJ, Crewick KC, Eden P, Taylor JT, Spindel ER (1995) Cloning of a receptor for amphibian [Phe13]bombesin distinct from the receptor for gastrin-releasing peptide: identification of a fourth bombesin receptor subtype (BB4). Proc Natl Acad Sci USA 92:6205–6209

    CAS  PubMed  Google Scholar 

  • Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H (1997) Implications of staging in lung cancer. Chest 112:242–248

    Google Scholar 

  • National Cancer Institute (1991) Annual cancer statistics review 1973–1988. Department of Health and Human Services, Bethesda MD (NIH publication no 91-2789)

    Google Scholar 

  • Nelson J, Donnelly M, Walkter B, Gray J, Shaw C, Murphy RF (1991) Bombesin stimulates proliferation of human breast cell cancer cells in culture. Br J Cancer 63:933–936

    CAS  PubMed  Google Scholar 

  • Nock B, Nikolopoulou A, Chiotellis E, Loudos G, Maints D, Reubi JC, Maina T (2003) (99mTc-Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 30:247–258

    CAS  PubMed  Google Scholar 

  • O’Byrne K,J, Halmos G, Pinski J, Groot K, Szepeshazi K, Schally AV, Carney DN (1994) Somatostatin receptor expression in lung cancer. Eur J Cancer 30:1682–1687

    Google Scholar 

  • Oka H, Jin L, Reubi J, Qian X, Scheithauer B, Fujii K, Kameya T, Lloyd R (1998) Pituitary adenylate-cyclase-activating polypeptide (PACAP) binding sites and PACAP / vasoactive intestinal polypeptide receptor expression in humam pituitary adenomas. Am J Pathol 153:1787–1796

    CAS  PubMed  Google Scholar 

  • O’Nilsson L, Kölby L, Wängberg B, Wigander A, Billig H, William-Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77:632–637

    Google Scholar 

  • Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Meacke HR (1997) DOTA-TOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 24:792–795

    CAS  PubMed  Google Scholar 

  • Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR (1998) Yittrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418

    Article  CAS  PubMed  Google Scholar 

  • Pacini F, Fugazzola L, Basolo F et al (1994) Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 78:826–829

    Article  CAS  PubMed  Google Scholar 

  • Pallela VR, Chakdar S, Rattan S, Thakur ML (1998a) Tc-99 m labeled VIP receptor agonist: functional and pharmacokinetic studies. J Nucl Med 39:64A

    Google Scholar 

  • Pallela VR, Reddy MVR, Senadhi VK, Thakur ML (1998b) Synthesis and evaluation of Tc-99m-labeled VIP as potential tumor imaging agents. J Nucl Med 39:226A

    Google Scholar 

  • Pallela VR, Thakur ML, Chakder S, Rattan S (1998c) Tc-99 m labeled VIP receptor agonist: functional studies. J Nucl Med 40:352–360

    Google Scholar 

  • Pangerl T, Peck-Radosavljevic M, Kaserer K, Niederle B, Gangl A, Virgolini I (1997) Somatostatin (SST)rand VIP receptor subtype gene expression in human tumors. Eur J Nucl Med 24:995A

    Google Scholar 

  • Panetta R, Patel YC (1994) Expression of mRNA for all five human somatostatin receptors (hSSTR-1-5) in pituitary tumors. Life Sci 56:333–342

    Article  CAS  Google Scholar 

  • Patz EF, Lowe VJ, Hoffman JM et al (1994) Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18] fluoro-2-deoxy-D-glucode. Radiology 191:379–382

    PubMed  Google Scholar 

  • Parker SL, Tong T, Bolden S, Wingo PA (1997) Cancer statistics 1997. Ca Cancer J Clin 47:5–27

    CAS  PubMed  Google Scholar 

  • Peck-Radosavljevic M, Yang Q, Leimer M, Bischof C, Virgolini I (1998) Thr somatostatin receptor (sstr) subtype 3 acts as an acceptor of vasoactive intestinal peptide (VIP). Gastroenterology 114:1172A

    Google Scholar 

  • Pincus DW, DiCicco-Bloom EM, Black IB (1990) Vasoactive intestinal polypeptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343:564–567

    Article  CAS  PubMed  Google Scholar 

  • Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E (1984) Long-acting and selective supression of growth hormon secretion by somatostatin analogue SMS 201–995 in acromegaly. Lancet 6:782–784

    Google Scholar 

  • Poinot-Chazel C, Portier M, Bouaboula M, Vita N, Pecceu F, Gully D, Monroe JG, Maffrand JP, Le Fur G, Casellas P (1996) Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24. Biochem J 320:145–151

    CAS  PubMed  Google Scholar 

  • Postema PTE, de Herder WW, Reubi JC, Oei HY, Kwekkeboom DJ, Bruining HJ, van Toor H, Hennemann G, Krenning EP (1996) Somatostatin receptor scintigraphy in non-medullary thyroid cancer. Digestion 57:36–37

    PubMed  Google Scholar 

  • Raderer M, Becherer A, Kurtaran A, Angelberger P, Li S, Leimer M, Weinländer G, Kornel G, Kletter K, Scheithauer W, Virgolini I (1996) Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy. J Nucl Med 37:1480–1487

    CAS  PubMed  Google Scholar 

  • Raderer M, Pangerl T, Leimer T, Valencak J, Kurtaran A, Hamilton G, Scheithauer W, Virgolini I (1998a) Expression of human somatostatin receptor subtyp 3 in pancreatic cancer in vitro and in vivo. J Natl Cancer Inst 90:1666–1668

    Article  CAS  PubMed  Google Scholar 

  • Raderer M, Kurtaran A, Yang Q, Susan Meghdadi, Vorbeck Friedrich, Heijn Michael, Angelberger P, Kornek G, Pidlich J, Scheithauer W, Virgolini I (1998b) Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer. J Nucl Med 39:1570–1575

    CAS  PubMed  Google Scholar 

  • Raderer M, Kurtaran A, Hejn M, Vorbeck T, Angelberger P, Scheithauer W, Virgolini I (1998c) 123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer. Br J Cancer 78:1–5

    CAS  PubMed  Google Scholar 

  • Raderer M, Valencak J, Pfeffler F, Drach J, Pangerl T, Kurtaran A, hejna M, Vorbeck F, Chott A, Virgolini I (1999) Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. J Natl Cancer Inst 21:716–718

    Google Scholar 

  • Raderer M, Traub T, Formanek M, Virgolini I, Österreicher C, Fiebiger W, Penz M, Jäger U, Pont J, Chott A, Kurtaran A (2001) Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer 85:1462–1466

    Article  CAS  PubMed  Google Scholar 

  • Rainhardt MJ, Moser E (1996) An update on diagnostic methods in the investigation of disease of the thyroid. Eur J Nucl Med 23:587–594

    Google Scholar 

  • Rehfeld JF, van Solinge WW (1994) The tumor biology of gastrin and cholecytokinin. Adv Cancer Res 63:295–347

    CAS  PubMed  Google Scholar 

  • Reichlin S (1983) Somatostatin. N Engl J Med 309:1556–1563

    CAS  PubMed  Google Scholar 

  • Rettenbacher M, Reubi J (2001) Localization and characterization of neuropeptide receptors in human colon. Nauyn Schmiedbergs Arch Pharmacol 364:291–301

    CAS  Google Scholar 

  • Reubi JC (1995) In vitro identification of vasoactive peptide receptors in human tumors: implications for tumor imaging. J Nucl Med 36:1846–1853

    CAS  PubMed  Google Scholar 

  • Reubi JC, Waser B (2003) Concomittant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793

    CAS  PubMed  Google Scholar 

  • Reubi JC, Maurer K, von Werder K, Torhorst J, Klijn GM, Lamberts SWJ (1989) Somatostatin receptors in human endocrine tumors. Cancer Res 47:551–558

    Google Scholar 

  • Reubi JC, Waser B, Sheppard M, Macaulay Y (1990) Somatostatin receptors are present in small-cell but not in non-small primary lung carcinomas: relationship to EGF-receptors. Int J Cancer 45:269–274

    CAS  PubMed  Google Scholar 

  • Reubi JC, Schaer JC, Waser B, Mengold G (1994) Expression and localization of somatostatin receptor SSTR1, SSTR2 and SSTR3 mRNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455–3459

    CAS  PubMed  Google Scholar 

  • Reubi JC, Schaer JC, Waser B (1997) Cholecytochinin (CCK)-A and CCK-B/Gastrin receptors in human tumors. Cancer Res 60:3150–3112

    Google Scholar 

  • Reubi JC, Waser B, Friess H, Buchler M, Laissue J (1998) Neurotensin receptors: a new marker for human ductal pancreatic adenocarcinoma. Gut 42:546–550

    CAS  PubMed  Google Scholar 

  • Reubi JC, Walser B, Schaer JC, Laissue JA (1999) Neurotensin receptors in human neoplasms: high incidence in Erwing’s sarcomas. Int J Cancer 82:213–218

    Article  CAS  PubMed  Google Scholar 

  • Reubi JC, Schar JC, Waser B, Wenger B, Heppeler A, Schmitt JS, Macke HR (2000a) Affinity profiles for human somatostatin receptor subtypes SST1-5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282

    Article  CAS  PubMed  Google Scholar 

  • Reubi JC, Läderach U, Waser B, Gebbers J-O, Robberecht P, Laissue JA (2000b) Vasoactive intestinal peptide/pituitary adenylate cayclase activating peptide receptor subtypes in human tumors and their tissues of origin. Cancer Res 60:3105–3112

    CAS  PubMed  Google Scholar 

  • Robberecht P, de Neef P, Gourlet P, Cauvin A, Coy DH, Christophe J (1989) Pharmacological characterization of the novel helodermin/VIP receptor present in human SUP-T1 lymphoma cell membranes. Regul Pept 26:117–126

    CAS  PubMed  Google Scholar 

  • Robberecht P, Vertongen P, Velkeniers B, de Neef P, Vergani P, Raftopoulos C, Brotchi J, Hooghe-Peters EL, Christophe J (1993) Receptors of pituitary adenylate cyclase activating peptides in human pituitary adenomas. J Clin Endocrinol Metab 77:1235–1239

    Article  CAS  PubMed  Google Scholar 

  • Robberecht P, Woussen-Colle MC, Vertongen P, de Neef P, Hou X, Salmon I, Brotchi J (1994) Expression of pituitary adenylate cyclase activating polypeptide (PACAP) receptors in human glial cell tumors. Peptides 15:661–665

    Article  CAS  PubMed  Google Scholar 

  • Rogers BE, Bigott HM, McCarthy DW, Della Manna D, Kim J, Sharp TL, Welch MJ (2003) MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu labeled analogue. Bioconjug Chem 14:756–763

    Article  CAS  PubMed  Google Scholar 

  • Rohrer L, Raulf F, Bruns C, Buetter R, Hofstaedter F, Schüle R (1993) Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 90:4196–4200

    CAS  PubMed  Google Scholar 

  • Rosenberg L, Brown RA (1991) Sandostatin in the management of nonendocrine gastrointestinal and pancreatic disorders: a preliminary study. Cancer J Surg 34:223–229

    CAS  Google Scholar 

  • Said SI, Foloona GR (1975) Elevated plasma and tissue levels of vasoactive intestinal peptide in the watery diarrhea syndrome. N Engl J Med 293:155–158

    CAS  PubMed  Google Scholar 

  • Said SI, Mutt V (1970) Polypeptide with broad biological activity. Isolation from small intestine. Science 169:1217–1218

    CAS  PubMed  Google Scholar 

  • Saurin JC, Rouault JP, Abello J, Berger F, Remy L, Chayvialle JA (1999) High gastrin releasing peptide receptor mRNA level is related to tumour differentiation and lymphatic vessel invasion inhuman colon cancer. Eur J Cancer 35:125–132

    Article  CAS  PubMed  Google Scholar 

  • Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752–755

    CAS  Google Scholar 

  • Schaer JC, Waser B, Mengold G, Reubi JC (1997) Somatostatin receptor subtypes sst1, sst2, sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography. Int J Cancer 70:530–537

    Article  CAS  PubMed  Google Scholar 

  • Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G (2003a) Somatostatin receptor scintigraphy with 111In-pentreotide in non-functioning gastroenteropancreatic neuroendocrine tumors. Int J Oncol 23:1687–1695

    CAS  PubMed  Google Scholar 

  • Schillaci O, Spanu A, Scopinaro F, Falchi A, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Maddedu G (2003b) Somatostatin receptor scintigraphy in liver metastases detection from gastroenteropancreatic neuroendocrine tumors. J Nucl Med 44:359–368

    CAS  PubMed  Google Scholar 

  • Schlag P, Lehner B, Strauss LG, Georgi P, Herfarth C(1989) Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg 124:197–200

    CAS  PubMed  Google Scholar 

  • Schmidt M, Fischer E, Dietlein M, Nichel O, Weber K, Moka D, Stennert E, Schicha H (2002) Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas. Eur J Mucl Med Mol Imaging 29:1571–1580

    CAS  Google Scholar 

  • Schulz S, Helmholz T, Schmitt J, Franke K, Otto HJ, Weise W (2002) True positive somatostatin receptor scintigraphy in primary brest cancer correlates with expression of sst2A and sst5. Breast Cancer Res Treat 72:221–226

    Article  CAS  PubMed  Google Scholar 

  • Scopinaro F, Varvarigou AD, Ussof W, de Vincentis G, Sourlingas TG, Evangelatos GP, Datsteris J, Archimandritis SC (2002) Technitium labeled bombesin-like peptide: preliminary report on breast cancer uptake in patients. Cancer Biother Radiopharm 17:327–335

    Article  CAS  PubMed  Google Scholar 

  • Scopinaro F, De Vincentis G, Varvarigou AD, Laurenti C, Iori F, Remediani S, Chiarini S, Stella S (2003a) 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes. Eur J Nucl Med Mol Imaging 30:1378–1382

    Article  PubMed  Google Scholar 

  • Scopinaro F, de Vincentis G, Corazziai E, Osti MF, Covotta A, Pallotta S, Remedianin S, Prosperi D, Monteleone F, Varvarigou A (2003b) Detection of colon cancer and invaded nodes with 99mTc-Bombesin. Preliminary data. Eur J Nucl Med Mol Imaging 30:P16

    Article  Google Scholar 

  • Seethalakshmi L, Mitra SP, Dobner PR, Menon M, Carraway RE (1997) Neurotensin receptor expression in prostatic cancer cell line and growth effect of NT at physiological concentrations. Prostate 31:183–192

    Article  CAS  PubMed  Google Scholar 

  • Seidman H, Mushnick MH, Gelb SK, Silverberg E (1985) Probability of eventually developing or dying of cancer: United States. CA Cancer J Clin 35:36–56

    CAS  PubMed  Google Scholar 

  • Shirzad M, Leimer M, Lister-James J, Moyer BR, Angelberger P, Virgolini I (1998) Preclinical characterization of a 99m-technetium labeled vasoactive intestinal peptide (VIP) receptor imaging peptide. Eur J Nucl Med 25:977A

    Google Scholar 

  • Siegelman S, Khouri N, Leo F, Fishman EK, Braverman RM, Zerhouni EA (1986) Solitary pulmonary nodules: CT assessment. Radiology 160:307–312

    CAS  PubMed  Google Scholar 

  • Smith-Jones P, Bischof C, Leimer M, Gludovac D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Hamilton G, Kaserer K, Steiner G, Schlagbauer-Wadl H, Mäcke H, Virgolini I (1998) ”MAURITIUS” a novel somatostatin analog for tumor diagnosis and therapy. J Nucl Med 39:223A

    Google Scholar 

  • Smith-Jones P, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, Peck-Radosavljevic M, Steiner G, Virgolini I (1999) ”MAURITIUS”: a novel tumor diagnostic and therapeutic somatostatin analog. Endocrinology 140:5136–5148

    Article  CAS  PubMed  Google Scholar 

  • Spindel ER, Giladi E, Brehm P, Goodman RH, Sgerson TP (1990) Cloning and functional characterization of a complementary DANN encoding the murine fibroblast bombesin/gastrin-releasing peptide receptor. Mol Endocrinol 4:1956–1963

    CAS  PubMed  Google Scholar 

  • Sreedharan SP, Kodama KT, Peterson KE, Goetzl EJ (1989) Distinct subjects of somatostatin receptors on cultured human lymphocytes. J Biol Chem 264:949–952

    CAS  PubMed  Google Scholar 

  • Sreedharan SP, Robichon A, Peterson KE, Goetzl EJ (1991) Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci USA 88:4986–4990

    CAS  PubMed  Google Scholar 

  • Stiefel F, Morant R (1993) Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Supp Care Cancer 1:57–58

    CAS  Google Scholar 

  • Stokkel MP, Reigman HI, Verkooijen RB, Smith JW (2003) Indium-111-Octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I-131. J Cancer Res Clin Oncol 129:287–294

    CAS  PubMed  Google Scholar 

  • Sun B, Halmos G, Schally AV, Wang X, Martinez M (2000) Pesence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancer. Prostate 42:295–303

    Article  CAS  PubMed  Google Scholar 

  • Svoboda M, Tastenoy M, van Rampelsbergh J, de Neef P, Waelbroeck M, Robberecht O (1994) Molecular cloning and functional characterization of a human VIP receptor from sup-T1 lymphoblasts. Biochem Biophys Res Commun 205:1617–1624

    Article  CAS  PubMed  Google Scholar 

  • Taucher S, Kurtaran A, Leimer M, Angelberger P, Pangerl T, Beck M, Gnant M, Jakesz R, Virgolini I (1996) Validation of VIP and somatostatin receptor scanning in primary breast cancer. Eur J Nucl Med 23:1094A

    Google Scholar 

  • Tenenbaum F, Lumbroso J, Schlumberger M, Caillou B, Fragu P, Parmentier C (1995) Radiolabeled somatostatin analog scintigraphy in differentiated thyroid carcinoma. J Nucl Med 36:807–810

    CAS  PubMed  Google Scholar 

  • Thakur ML, Kolan H, Li J, Wiaderkiewicz, Pallela VR, Duggaraju R, Schally AV (1997) Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol 24:105–113

    CAS  PubMed  Google Scholar 

  • Thakur ML, Marcus CS, Saeed S, Pallela V, Minami C, Diggles L, Le Pham H, Ahdoot R, Kalinowski EA (2000) 99mTC-labeled vasoactive intestinal peptide analog for rapid localization of tumors in humans. J Nucl Med 41:107–110

    CAS  PubMed  Google Scholar 

  • Thomas F, Brambrilla E, Friedmann A (1994) Transcription of somatostatin receptor subtype 1 and 2 genes in lung cancer. Lung Cancer 11:111–114

    Article  CAS  PubMed  Google Scholar 

  • Traub T, Petkov V, Ofluoglu S, Pangerl P, Raderer M, Fueger B, Schima W, Kurtaran A, Dudczak R, Vrgolini I (2001) 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 42:1309–1315

    CAS  PubMed  Google Scholar 

  • Ullrich CD, Holtmann Martin, Miller LJ (1998) Secretin and vasoactive intestinal peptide receptors: members of a unique family of G protein-coupled receptors. Gastroenterology 114:382–397

    Google Scholar 

  • Usdin TB, Bonner TI, Mezey E (1994) Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology 135:2662–2680

    Article  CAS  PubMed  Google Scholar 

  • Vallabhajosula S, Moyer BR, Lister-James J, McBride BJ, Lipszyc H, Lee H, Bastidas D, Dean RT (1996) Preclinical evaluation of technetium-99m-labeled somatostatin receptor-binding peptides. J Nucl Med 37:1016–1022

    CAS  PubMed  Google Scholar 

  • Van der Wiele C, Dumont F, Vanden Broecke R, Oosterlinck W, Cocquyt V, Serreyn R, Peers S, Thornback J, Slegers G, Dierckx RA (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor expressing malignancies: a feasibility study. Eur J Nucl Med 27:1694–1699

    PubMed  Google Scholar 

  • Van de Wiele C, Dumont F, Dierckx RA et al (2001) Biodistribution and dosimetry of 99mTc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J Nucl Med 42:1722–1727

    PubMed  Google Scholar 

  • Van Dyke JA, Stanley RJ, Berland LL (1985) Pancreatic imaging. Ann Intern Med 102:212–217

    PubMed  Google Scholar 

  • Van Eijck CHJ, Krenning EP, Bootsma A, Oei HY, van Pel R, Lindemans J, Jeekel J, Reubi JC, Lamberts SWJ (1994) Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343:640–643

    PubMed  Google Scholar 

  • Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H (1997) Pituitary adenylate cyclase-activating peptide and ist receptors: from structure to function. Pharmacol Rev 50:265–324

    Google Scholar 

  • Verner JV, Morrison AB (1958) Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia. Am J Med 25:374–380

    Article  CAS  PubMed  Google Scholar 

  • Vertongen P, Devalck C, Sariban E, De Laet MH, Martelli H, Paraf F, Helardot P, Robberecht P (1996) Pituitary adenylate cyclase activating peptide and ist receptors are expressed in human neuroblastomas. J Cell Physiol 167:36–46

    Article  CAS  PubMed  Google Scholar 

  • Vikic-Topic S, Raisch KP, Kvols L, Vuk-Pavlovic S (1995) Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumors, and renal cell carcinoma. J Clin Endocrinol Metab 80:2974–2979

    Article  CAS  PubMed  Google Scholar 

  • Vincent JP, Mazella J, Kitabgi P (1999) Neurotensin and neurotensin receptors. Trends Pharmacol Sci 20:302–309

    Article  CAS  PubMed  Google Scholar 

  • Vinik AI, McLeod MK, Fig LM, Shapiro B, Lloyd RV, Cho K (1989) Clinical features, diagnosis, and localization of carcinoid tumors and their management. Gastroenterol Clin North Am 18:865–896

    CAS  PubMed  Google Scholar 

  • Virgolini I (1997) Mack Forster Award Lecture: receptor nuclear medicine: somatostatin receptor scintigraphy for diagnosis and treatment of tumor patients. Eur J Clin Invest 27:793–800

    CAS  PubMed  Google Scholar 

  • Virgolini I, Yang Q, Li S, Angelberger P, Neuhold N, Niederle B, Scheithauer W, Valent P (1994a) Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 54:690–700

    CAS  PubMed  Google Scholar 

  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Banyai S, Yang Q, Li S, Banyai M, Pidlich J, Niederle B, Scheithauer W, Valent P (1994b) Vasoactive intestinal peptide (VIP) receptor imaging for the localisation of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331:1116–1121

    Article  CAS  PubMed  Google Scholar 

  • Virgolini I, Kurtaran A, Raderer M, Leimer M, Angelberger P, Havlik E, Li S, Scheithauer W, Niederle B, Valent P, Eichler HG (1995) Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36:1732–1739

    CAS  PubMed  Google Scholar 

  • Virgolini I, Angelberger P, Li S, Yang Q, Kurtaran A, Raderer M, Neuhold N, Kaserer K, Leimer M, Peck-Radosavljevic M, Scheithauer W, Niederle B, Eichler HG, Valent P (1996a) In vitro and in vivo studies of three radiolabelled somatostatin analoges: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT. Eur J Nucl Med 23:1388–1399

    Article  CAS  PubMed  Google Scholar 

  • Virgolini I, Pangerl T, Bischof C, Leimer M, Yang Q, Peck-Radosavljevic M, Kaserer K, Niederle B, Angelberger P, Gangl A, Valent P (1996b) Somatostatin (SST) and vasoactive intestinal peptide (VIP) receptor (R) subtype gene expression. Eur J Nucl Med 23:1101A

    Article  Google Scholar 

  • Virgolini I, Raderer M, Kurtaran A, Angelberger P, Yang Q, Radosavljevic M, Leimer M, Kaserer K, Li S, Kornek G, Hübsch P, Niederle B, Pidlich J, Scheithauer W, Valent P (1996c) 123I-Vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 23:685–692

    CAS  PubMed  Google Scholar 

  • Virgolini I, Pangerl T, Bischof C, Smith-Jones P, Peck-Radosavljevic M (1997) Somatostatin receptor subtype expression in human tissues: a prediction for diagnosis and treatment of cancer? Eur J Clin Invest 27:645–647

    CAS  PubMed  Google Scholar 

  • Virgolini I, Leimer M, Hirschmaker H, Lastoria S, Bischof C, Muto P, Pangerl T, Gludovacz D, Peck-Radosavljevic M, Lister-James J, Hamilton G, Kaserer K, Valent P, Dean R (1998a) Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res 58:1850–1859

    CAS  PubMed  Google Scholar 

  • Virgolini I, Kurtaran A, Leimer M, Kaserer K, Peck-Radosavljevic M, Angelberger P. Hübsch P, Dvorak M, Valent P, Niederle B (1998b) Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy. J Nucl Med 39:1575–1579

    CAS  PubMed  Google Scholar 

  • Virgolini I, Szilvasi I, Angelberger P, Raderer M, Havlik E, Vorbeck F, Bischof C, Leimer M, Dorner G, Kletter K, Niederle B, Scheithauer W, Smith-Jones P (1998c) Indium-111-DOTA-lanreotide: biodistribution, safety and tumor dose in patients. J Nucl Med 39:1928–1936

    CAS  PubMed  Google Scholar 

  • Virgolini I, Smith-Jones P, Moncayo R, Kurtaran A, Wenger M, Raderer M, Havlik E, Angelberger P, Szilvaszi I, Zoboli S, Paganelli G, Riccabona G (1998d) 111-In/90-Y-DOTA-lanreotide scintigraphy and therapy: initial clinical results of “Mauritius”. Eur J Nucl Med 25:884A

    Google Scholar 

  • Virgolini I, Traub T, Ofluoglu S, Kurtaran A, Raderer M, Peck M, Leimer M, Angelberger P, Li S, Novotny C, Havlik E, Dudczak R, Lister-James J (1999) 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. Eur J Nucl Med 26:1154

    Google Scholar 

  • Virgolini I, Patri p, Novotny C, Traub T, Leimer M, Fuger B, Li SR, Angelberger P, Raderer M, Wogritsch S, Kurtaran A, Kletter K, Dudczak R (2001)Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 12[Suppl 2]:41–45

    Google Scholar 

  • Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P (2002) 111In-and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trail. Semin Nucl Med 32:148–155

    Article  PubMed  Google Scholar 

  • Vural G, Unlu M, Atasever T, Özur I, Özdemir A, Gökcora N (1997) Comparison of indium-111 octreotide and thallium-201 scintigraphy in patients mammographically suspected of having breast cancer: preliminary results. Eur J Nucl Med 24:312–315

    CAS  PubMed  Google Scholar 

  • Wada E, Way J, Shapira H, Kusano K, Lebacq-Verheyden AM, Coy D, Jensen R, Battey J (1991) cDNA cloning, characterization and brain region-specific expression og a neuromedin-B preferring bombesin receptor. Neuron 6:421–430

    Article  CAS  PubMed  Google Scholar 

  • Walsh JH (1994a) Gastrointestinal hormones. In: Johnson LR (ed) Physiology of the gastrointestinal tract, 3rd edn. Raven Press, New York, pp 1–28

    Google Scholar 

  • Walch JH (1994b) Gastrin. GUT peptides: biochemistry and physiology. In: Walch JH, Dockray GJ (eds) Physiology of the gastrointestinal tract, 3rd edn. Raven Press, New York, pp 75–121

    Google Scholar 

  • Wang QJ, Knezetic JA, Schally AV, Pour PM, Adrian TE (1996) Bombesin stimulate proliferation of human pancreatic cancer cells through an autocrine pathway. Int J Cancer 68:528–534

    CAS  PubMed  Google Scholar 

  • Wang KP, Kelly SJ, Britt JE (1988) Percutaneous needle aspiration biopsy of chest lesions. New instrument and new technique. Chest 9:993–997

    Google Scholar 

  • Wang L, Friess H, Zhu Z, Graber H, Zimmermann A, Korc M, Reubi JC, Buchler MW (2000) Neurotensin receptor-1 mRNA analysis in normal pancreas and pancreatic disease. Clin Cancer Res 6:566–571

    CAS  PubMed  Google Scholar 

  • Wank SA, Pisegna JR, de Weerth A (1992) Brain and gastrointestinal cholecytochinin receptor family: structure and functional expression. Proc Natl Acad Sci USA 89:8691–8695

    CAS  PubMed  Google Scholar 

  • Warshaw AL, Fernandez-del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–465

    CAS  PubMed  Google Scholar 

  • Wester HJ, Schottelius M, Scheidhauer K, Meisetschlager G, Herz M, Rau FC, Reubi JC, Schweiger M (2003) PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue octreotide. Eur J Nucl Med Mol Imaging 30:117–122

    CAS  PubMed  Google Scholar 

  • World Health Organization (1981) Histologic typing of lung cancer, 2nd edn. WHO, Geneva

    Google Scholar 

  • Wraight EP, Bard DR, Maughan TS, Knight CG, Page-Thomas DP (1992) The use of a chelating derivate of a á melanocyte stimulating hormone for the clinical imaging of malignant melanoma. Br J Radiol 65:112–118

    CAS  PubMed  Google Scholar 

  • Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S (1992a) Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract and kidney. Proc Natl Acad Sci USA 89:251–255

    CAS  PubMed  Google Scholar 

  • Yamada Y, Reisine S, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell I, Seino S (1992b) Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. Mol Endocrinol 6:2136–2142

    Article  CAS  PubMed  Google Scholar 

  • Yamada Y, Kagimoto S, Kubota A, Yasuda K, Masuda K, Someya Y, Ihara Y, Li Q, Imura H, Seino S, Seino Y (1993) Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and fifth (hSSTR5) human somatostatin receptor subtypes. Biochem Biophys Res Commun 195:844–852

    CAS  PubMed  Google Scholar 

  • Yamada M, Yamada M, Lombet A, Forgez P, Rostène W (1998) Distinct function characteristics of levobastine sensitive rat neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Life Sci 62:375–380

    Google Scholar 

  • Yasuda K, Res-Domiano S, Breder CA, Law SF, Saper C, Reisine T, Bell GI (1992) Cloning of a novel somatostatin receptor, SST3, coupled to adenylate cyclase. J Biol Chem 267:20422–20428

    CAS  PubMed  Google Scholar 

  • Zia H, Hida T, Jakowlew S, Birrer M, Gozes Y, Reubi JC, Fridkin M, Gozes I, Moody TW (1996) Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res 56:3486–3489

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinic of Nuclear Medicine, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria

    Irene Virgolini MD (Professor) & T. Traub-Weidinger MD

Authors
  1. Irene Virgolini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Traub-Weidinger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Leuven, Germany

    A. L. Baert

  2. Heidelberg, Germany

    K. Sartor

  3. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, AR-144 CHS, Los Angeles, CA, 90095-6942, USA

    Christiaan Schiepers MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Virgolini, I., Traub-Weidinger, T. (2006). Peptide Imaging. In: Baert, A.L., Sartor, K., Schiepers, C. (eds) Diagnostic Nuclear Medicine. Medical Radiology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30005-8_10

Download citation

  • DOI: https://doi.org/10.1007/3-540-30005-8_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-42309-6

  • Online ISBN: 978-3-540-30005-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation